Report Title:
Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2017 Published On: December 2017
Category: Life Sciences
Pages: 80
Report Overview: Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H2 2017 Summary Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H7N9 Subtype Infections Infectious Disease pipeline landscape. Avian influenza A H7N9 is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs Report Highlights Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections Infectious Disease, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Influenza A Virus, H7N9 Subtype Infections Infectious Disease pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in PreRegistration, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 8, 11 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively. Influenza A Virus, H7N9 Subtype Infections Infectious Disease pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope The pipeline guide provides a
24marketreports | International +1 646 781 7170 | www.24marketreports.com
snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections Infectious Disease. The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections Infectious Disease by companies and universities/research institutes based on information derived from company and industryspecific sources. The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections Infectious Disease therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections Infectious Disease therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections Infectious Disease Reasons to buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections Infectious Disease. Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections Infectious Disease pipeline depth and focus of Indication therapeutics. Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.
Table of Contents: Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Influenza A Virus, H7N9 Subtype Infections Overview Influenza A Virus, H7N9 Subtype Infections Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Products under Development by Universities/Institutes Influenza A Virus, H7N9 Subtype Infections Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Influenza A Virus, H7N9 Subtype Infections Companies Involved in Therapeutics Development AusBio Ltd Beijing Minhai Biotechnology Co Ltd Cocrystal Pharma Inc EpiVax Inc Genentech Inc iBio Inc Inovio Pharmaceuticals Inc Karyopharm Therapeutics Inc Medicago Inc Medigen Vaccine Biologics Corp Moderna Therapeutics Inc NanoViricides Inc Novavax Inc Ology Bioservices Inc Sanofi Pasteur SA Shionogi & Co Ltd VirionHealth Ltd Vivaldi Biosciences Inc Influenza A Virus, H7N9 Subtype Infections Drug Profiles AT501 Drug Profile Product Description Mechanism Of Action R&D Progress baloxavir marboxil Drug Profile Product Description Mechanism Of Action R&D Progress CC42344 Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] monovalent vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] monovalent vaccine Drug Profile Product Description Mechanism Of Action R&D Progress
24marketreports | International +1 646 781 7170 | www.24marketreports.com
influenza [strain A/H7N9] monovalent vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] monovalent vaccine 1 Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] monovalent vaccine 2 Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] split virion vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] virus like particle vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] virus like particle, monovalent vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] whole virion vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] whole virion vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] vaccine Drug Profile Product Description
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Mechanism Of Action R&D Progress influenza [strain A/H7N9] vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] vaccine Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H7N9] vaccine Drug Profile Product Description Mechanism Of Action R&D Progress MD2009 Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections Drug Profile Product Description Mechanism Of Action R&D Progress mRNA1851 Drug Profile Product Description Mechanism Of Action R&D Progress NVINF1 Drug Profile Product Description Mechanism Of Action R&D Progress NVINF2 Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections Drug Profile Product Description Mechanism Of Action R&D Progress
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Small Molecules to Inhibit Neuraminidase A for Infectious Diseases Drug Profile Product Description Mechanism Of Action R&D Progress verdinexor Drug Profile Product Description Mechanism Of Action R&D Progress VH244 Drug Profile Product Description Mechanism Of Action R&D Progress Influenza A Virus, H7N9 Subtype Infections Dormant Projects Influenza A Virus, H7N9 Subtype Infections Product Development Milestones Featured News & Press Releases Sep 08, 2017: Shionogi to Present New Data on S033188, a CapDependent Endonuclease Inhibitor for Treatment of Influenza, at the 6th European Scientific Working Group in Influenza Conference Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
Get More Information about the Report: Report URL: https://www.24marketreports.com/life-sciences/influenza-a-virus-h7n9-subtype-infectionspipeli ne-review-h2-market-10 To get Report Sample: https://www.24marketreports.com/request-sample/influenza-a-virus-h7n9-subtype-infectionspip eline-review-h2-market-10
24marketreports | International +1 646 781 7170 | www.24marketreports.com